DTILPrecision BioSciences, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $6.63 · now $6.63 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, DTIL has typically landed between $4.54 and $8.97 — a range of −31.5% to +35.4% from the issuance price $6.63.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,857 overlapping 1 month windows · 2019-03-28 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($6.63) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where DTIL has typically landed a month from the 2026-09-16 close of $6.63 — the range is history, not a prediction.

$4.54worst · -31.5%$8.97best · +35.4%
  • now $6.63 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $6.23 (-6.0%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $5.41–$7.05
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.54–$8.97
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,857 windows spanning 2019-03-28 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-11-29−47.7%−47.7%+0.0%
2021-12-28−46.3%−46.3%+0.0%
2020-01-10−45.9%−45.9%+0.0%
3 best
2019-10-29+180.6%+0.0%+180.6%
2019-10-30+171.7%−0.8%+178.0%
2019-11-05+169.0%+0.0%+169.0%

1,857 overlapping windows · 2019-03-28 – 2026-09-16 · not cherry-picked

Pending catalysts

  • November 2029 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~8 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
43%
−0.7%
n=7
Feb
43%
+8.7%
n=7
Mar
14%
−15.1%
n=7
Apr
50%
−2.8%
n=8
May
50%
−0.2%
n=8
Jun
38%
−2.8%
n=8
Jul
25%
−5.8%
n=8
Aug
63%
−0.2%
n=8
Sep
25%
−8.0%
n=8
Oct
43%
+0.5%
n=7
Nov
43%
+33.1%
n=7
Dec
14%
−22.1%
n=7

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$9$42026-02-18: 4 insider sales, $148K — Amoroso Michael, Kelly John Alexander, SMITH J. JEFFERSON, Scimeca Dario2026-01-22: 1 insider sale, $145K — Amoroso Michael2026-01-21: 3 insider sales, $138K — Kelly John Alexander, SMITH J. JEFFERSON, Scimeca Dario2025-12-16: 2 insider purchases, $27K — Germano Geno J, Frankel Stanley2025-12-15: 1 insider purchase, $7K — Brown Melinda2025-11-03: 3 insider sales, $35K — Amoroso Michael, Kelly John Alexander, Scimeca Dario2025-09-26: 1 insider purchase, $13K — Frankel Stanley2025-09-22: 1 insider purchase, $7K — Brown Melinda2025-09: 2 open-market purchases, $20K2025-11: 3 open-market sales, $35K2025-12: 3 open-market purchases, $34K2026-01: 4 open-market sales, $283K2026-02: 4 open-market sales, $148K↑ buys↓ salesdirector Amoroso Michael — Sale on 2026-02-18, filed 1 day after the tradeofficer Kelly John Alexander — Sale on 2026-02-18, filed 1 day after the tradeofficer SMITH J. JEFFERSON — Sale on 2026-02-18, filed 1 day after the tradeofficer Scimeca Dario — Sale on 2026-02-18, filed 1 day after the tradedirector Amoroso Michael — Sale on 2026-01-22, filed same dayofficer Kelly John Alexander — Sale on 2026-01-21, filed 1 day after the tradeofficer SMITH J. JEFFERSON — Sale on 2026-01-21, filed 1 day after the tradeofficer Scimeca Dario — Sale on 2026-01-21, filed 1 day after the tradedirector Germano Geno J — Purchase on 2025-12-16, filed 1 day after the tradedirector Frankel Stanley — Purchase on 2025-12-16, filed 1 day after the tradedirector Brown Melinda — Purchase on 2025-12-15, filed 2 days after the tradedirector Amoroso Michael — Sale on 2025-11-03, filed 1 day after the tradeofficer Kelly John Alexander — Sale on 2025-11-03, filed 1 day after the tradeofficer Scimeca Dario — Sale on 2025-11-03, filed 1 day after the tradedirector Frankel Stanley — Purchase on 2025-09-26, filed 4 days after the tradedirector Brown Melinda — Purchase on 2025-09-22, filed 2 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-02-18Amoroso MichaeldirectorSale20,559 @ $3.84$79K−7.8% of holding+78.4%+108.1%243,392Form 4 · filed 1 day after the trade
2026-02-18Kelly John AlexanderofficerSale8,149 @ $3.84$31K−6.1% of holding+78.4%+108.1%125,883Form 4 · filed 1 day after the trade
2026-02-18SMITH J. JEFFERSONofficerSale4,925 @ $3.84$19K−3.9% of holding+78.4%+108.1%121,926Form 4 · filed 1 day after the trade
2026-02-18Scimeca DarioofficerSale4,925 @ $3.84$19K−8.0% of holding+78.4%+108.1%56,457Form 4 · filed 1 day after the trade
2026-01-22Amoroso MichaeldirectorSale34,799 @ $4.17$145K−15.1% of holding−6.1%+63.7%196,154Form 4 · filed same day
2026-01-21Kelly John AlexanderofficerSale15,213 @ $4.03$61K−12.5% of holding−6.1%+74.5%106,448Form 4 · filed 1 day after the trade
2026-01-21SMITH J. JEFFERSONofficerSale10,200 @ $4.03$41K−8.5% of holding−6.1%+74.5%110,184Form 4 · filed 1 day after the trade
2026-01-21Scimeca DarioofficerSale8,854 @ $4.03$36K−16.5% of holding−6.1%+74.5%44,715Form 4 · filed 1 day after the trade
2025-12-16Germano Geno JdirectorPurchase3,000 @ $4.72$14K+14.4% of holding−18.2%+30.4%23,883Form 4 · filed 1 day after the trade
2025-12-16Frankel StanleydirectorPurchase2,700 @ $4.70$13K+16.1% of holding−18.2%+30.4%19,478Form 4 · filed 1 day after the trade
2025-12-15Brown MelindadirectorPurchase1,381 @ $4.97$7K+6.3% of holding−20.7%+26.0%23,346Form 4 · filed 2 days after the trade
2025-11-03Amoroso MichaeldirectorSale3,409 @ $6.49$22K−2.9% of holding−31.3%−5.8%115,575Form 4 · filed 1 day after the trade
2025-11-03Kelly John AlexanderofficerSale1,303 @ $6.49$8K−1.7% of holding−31.3%−5.8%77,298Form 4 · filed 1 day after the trade
2025-11-03Scimeca DarioofficerSale665 @ $6.49$4K−2.3% of holding−31.3%−5.8%28,258Form 4 · filed 1 day after the trade
2025-09-26Frankel StanleydirectorPurchase2,700 @ $4.97$13K+19.2% of holding+38.4%+11.1%16,778Form 4 · filed 4 days after the trade
2025-09-22Brown MelindadirectorPurchase1,400 @ $4.89$7K+6.8% of holding+43.2%+33.2%21,965Form 4 · filed 2 days after the trade
2025-07-03Kelly John AlexanderofficerSale14,827 @ $4.26$63K−16.8% of holding+10.6%−15.4%73,485Form 4 · filed 5 days after the trade
2025-06-25Buehler KevindirectorPurchase5,076 @ $4.16$21K+22.0% of holding+16.5%−12.1%28,137Form 4 · filed 2 days after the trade
2025-06-25Brown MelindadirectorPurchase1,682 @ $4.14$7K+8.9% of holding+16.5%−12.1%20,565Form 4 · filed 2 days after the trade
2025-03-26Buehler KevindirectorPurchase4,523 @ $4.67$21K+51.9% of holding+20.8%−7.6%13,235Form 4 · filed 2 days after the trade
2025-03-26Brown MelindadirectorPurchase1,839 @ $4.75$9K+25.5% of holding+20.8%−7.6%9,057Form 4 · filed 2 days after the trade
2025-03-25Germano Geno JdirectorPurchase3,250 @ $5.30$17K+41.6% of holding+13.1%−14.8%11,057Form 4 · filed 2 days after the trade
2025-03-24Amoroso MichaeldirectorSale964 @ $5.56$5K−0.9% of holding+7.4%−29.7%109,540Form 4 · filed 1 day after the trade
2025-03-04Scimeca DarioofficerSale272 @ $4.91$1K−1.1% of holding−6.0%−13.0%25,000Form 4 · filed 1 day after the trade
2025-03-04SMITH J. JEFFERSONofficerSale154 @ $4.91$756−0.2% of holding−6.0%−13.0%87,805Form 4 · filed 1 day after the trade
2025-01-22SMITH J. JEFFERSONofficerSale10,287 @ $4.79$49K−10.5% of holding+20.4%−4.6%87,440Form 4 · filed same day
2025-01-22Scimeca DarioofficerSale8,928 @ $4.79$43K−26.8% of holding+20.4%−4.6%24,353Form 4 · filed same day
2025-01-21Amoroso MichaeldirectorSale36,838 @ $4.67$172K−25.6% of holding+28.0%+2.5%107,087Form 4 · filed 1 day after the trade
2024-12-30Germano Geno JdirectorPurchase3,605 @ $4.49$16K+85.8% of holding+15.3%−5.1%7,807Form 4 · filed 3 days after the trade
2024-12-27Buehler KevindirectorPurchase4,320 @ $4.88$21K+98.4% of holding+10.4%−13.3%8,712Form 4 · filed 4 days after the trade
2024-12-27Kelly John AlexanderofficerPurchase2,113 @ $4.75$10K+5.5% of holding+10.4%−13.3%40,186Form 4 · filed 4 days after the trade
2024-12-26Brown MelindadirectorPurchase3,016 @ $4.55$14K+71.8% of holding+3.9%−15.8%7,218Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

126 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-03Buehler KevindirectorAward / grant20,97920,979Form 4
2026-06-03Pire Shari LisadirectorAward / grant20,97920,979Form 4
2026-06-03Germano Geno JdirectorAward / grant20,97920,979Form 4
2026-06-03Frankel StanleydirectorAward / grant20,97920,979Form 4
2026-06-03Brown MelindadirectorAward / grant20,97920,979Form 4
2026-06-01SMITH J. JEFFERSONofficerAward / grant57,38957,389Form 4
2026-06-01Scimeca DarioofficerAward / grant107,604107,604Form 4
2026-06-01Amoroso MichaeldirectorAward / grant573,888573,888Form 4
2026-06-01Kelly John AlexanderofficerAward / grant193,688193,688Form 4
2026-05-20Pire Shari LisadirectorOption exercise21,0000Form 4
2026-05-20Brown MelindadirectorOption exercise21,0000Form 4
2026-05-20Germano Geno JdirectorOption exercise21,0000Form 4
2026-05-20Buehler KevindirectorOption exercise21,0000Form 4
2026-05-20Frankel StanleydirectorOption exercise21,0000Form 4
2026-05-20Pire Shari LisadirectorOption exercise21,00035,028Form 4
2026-05-20Frankel StanleydirectorOption exercise21,00040,478Form 4
2026-05-20Buehler KevindirectorOption exercise21,00049,137Form 4
2026-05-20Germano Geno JdirectorOption exercise21,00044,883Form 4
2026-05-20Pire Shari LisadirectorOption exercise21,00035,028Form 4
2026-05-20Brown MelindadirectorOption exercise21,00044,346Form 4
2026-05-20Frankel StanleydirectorOption exercise21,00040,478Form 4
2026-05-20Brown MelindadirectorOption exercise21,00044,346Form 4
2026-05-20Buehler KevindirectorOption exercise21,00049,137Form 4
2026-05-20Germano Geno JdirectorOption exercise21,00044,883Form 4
2026-02-17Scimeca DarioofficerOption exercise16,66761,382Form 4
2026-02-17Scimeca DarioofficerOption exercise16,66733,333Form 4
2026-02-17Kelly John AlexanderofficerOption exercise27,584134,032Form 4
2026-02-17Kelly John AlexanderofficerOption exercise27,58455,166Form 4
2026-02-17SMITH J. JEFFERSONofficerOption exercise16,667126,851Form 4
2026-02-17SMITH J. JEFFERSONofficerOption exercise16,66733,333Form 4
2026-02-17Amoroso MichaeldirectorOption exercise67,797263,951Form 4
2026-02-17Amoroso MichaeldirectorOption exercise67,797135,593Form 4
2026-01-21SMITH J. JEFFERSONofficerOption exercise16,219120,384Form 4
2026-01-21SMITH J. JEFFERSONofficerOption exercise16,219120,384Form 4
2026-01-20Kelly John AlexanderofficerOption exercise3,8880Form 4
2026-01-20Amoroso MichaeldirectorOption exercise8,8880Form 4
2026-01-20Amoroso MichaeldirectorOption exercise37,06937,069Form 4
2026-01-20Amoroso MichaeldirectorOption exercise69,42169,421Form 4
2026-01-20Kelly John AlexanderofficerOption exercise13,90013,901Form 4
2026-01-20Kelly John AlexanderofficerOption exercise26,57526,575Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.